Basilea

Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release →

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release →

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA agreement Basel, Switzerland, 26-6-2013 — /europawire.eu/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the Biomedical Advanced Research and Development … Read the full press release →

“El beneficio antes de provisiones alcanzó 23.559 millones de euros, lo que sitúa a Banco Santander como el tercer banco del mundo y muestra la capacidad de generación de beneficios que tiene el grupo una vez se normalice el nivel … Read the full press release →

Antonio TAJANI – Vicepresidente della Commissione europea, responsabile per l’Industria e l’Imprenditoria Berlaymont / Bruxelles 10-1-2013 — /europawire.eu/ — 1. Una rivoluzione culturale La Commissione ha adottato questa mattina il piano d’azione “Imprenditoria 2020”. Vorrei innanzitutto ringraziare i Vice Presidenti Vivian Reding e … Read the full press release →

Basel, Switzerland, 3-1-2013 — /europawire.eu/ — Basilea Pharmaceutica Ltd. (“Basilea”, SIX:BSLN) and its partner Astellas Pharma Inc. (“Astellas”) announced today that patient recruitment for the isavuconazole phase 3 registration study SECURE has been completed. Isavuconazole is an investigational intravenous (i. v.) … Read the full press release →